Leukemia Patients' hidden threat: fungal infections under microscope
NCT ID NCT05750706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better understand this risk, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, 00168, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can we make CAR-T cells last longer in leukemia?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Blood test clues could make antifungal dosing safer for transplant patients
- Tiny study aims to Fine-Tune fungal drug dosing during plasma exchange
- New combo therapy aims to boost survival in adult leukemia